1000 SKOKIE BLVD SUITE 350, WILMETTE, IL
Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease
.2
Shareholder votes
Investor Presentation
Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease
Reports First Quarter 2026 Financial Results and Provides Business Updates
Annual Report to Security Holders
Amended Annual Report
Q3
Q2
Q1
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Notice of Proposed Sale of Securities
Notice of Proposed Sale of Securities
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Schedule 13G - Ownership Report
Correspondence
Submission Upload